CCR6 antagonist 1
Based on 4 publication(s) in Google Scholar
CCR6 antagonist 1 is a CCR6 antagonist that inhibits the CCL20/CCR6 axis. CCR6 antagonist 1 can be used in the research of autoimmune-mediated inflammatory diseases, such as inflammatory bowel diseases (IBDs).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.30%
- No. CAS: 588674-64-0
- Fòrmula: C17H12F3NO2
- Peso molecular:319.28
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) CCR6 antagonist 1
More
Customer Validation & Images
-
Others
-
Cell Migration/Invasion Assay
-
Cell Migration/Invasion Assay
Actividad biológica
Descripciòn
IC50 & Target
[1]|
CCR6 |
In Vitro
CCR6 antagonist 1 (compound 1b, 50 μM, 3 h) blocks the CCL20-induced CD4+ T cell migration[1].
?
CCR6 antagonist 1 (30 nM-300 μM, 20 min) inhibits miniGi recruitment to CCR6 induced by CCL20, and β-arrestin-1 recruitment to CCR6 and CCR5 by CCL20 and CCL5 (5 nM), respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CCL20 (500 ng/mL)-induced CCR6+CD4+ T cell
-
Concentration:0.5, 5, 50 μM
-
Incubation Time:3 h
-
Result:Inhibited CCL20-induced cell migration at 50 μM.
In Vivo
? CCR6 antagonist 1 (1 mg/kg, s.c., twice, before and after zymosan treatment) shows anti-inflammatory effects
in Zymosan-induced peritonitis mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Murine model of colitis (5 mg/mouse TNBS-induced)[1]
-
Dosage:1 mg/kg
-
Administration:Subcutaneous injection (s.c.), twice daily for 3 days.
-
Result:Improved mice general conditions, attenuated macroscopic injury and counteracted neutrophils infiltration, both in the colon and in lungs.
-
Animal Model:Zymosan-induced peritonitis mice[1]
-
Dosage:1 mg/kg
-
Administration:Subcutaneous injection (s.c.), twice, before and after zymosan treatment
-
Result:Significantly reduced the total protein content and myeloperoxidase activity in the peritoneal lavage.
Chemical Information
-
No. CAS 588674-64-0
-
Appearance Solid
-
Peso molecular 319.28
-
Fòrmula C17H12F3NO2
-
Color White to off-white
-
SMILES
O=C(C1=C(C)C2=CC=CC=C2O1)NC3=CC=C(C(F)(F)F)C=C3
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 Mar 13;16(1):2493. PMID: 40082402
CCR6 antagonist 1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Mar 13;16(1):2493. [Abstract]
CCR6 antagonist 1 (50 μM). The effects of the inhibitor on each pathway were assessed by IPA analysis, and its effect on HE cell expansion after 7 days was observed.
-
Transl Res
Appendiceal B lymphocytes contribute to the pathogenesis of experimental colitis through fueling colonic CD4+ T polarization. [Abstract]2025 Sep 11:S1931-5244(25)00089-1. PMID: 40945653
CCR6 antagonist 1 purchased from MedChemExpress. Usage Cited in: Transl Res. 2025 Sep 11:S1931-5244(25)00089-1. [Abstract]
The number of migrating NCAPB and DSSAPB cells with or without CCR6 antagonist 1 treatment.
-
Int Immunopharmacol
2024 Jan 25:127:111332. PMID: 38071913
CCR6 antagonist 1 purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2024 Jan 25:127:111332. [Abstract]
Transwell migration assay: PBMCs isolated from MPE patients were placed in the upper chamber, and different conditions (medium, PE, MPE, MPE + CCR2 antagonist, MPE + CCR5 antagonist, or MPE + CCR6 antagonist 1 (20 μg/mL) ) were placed in the lower chamber.
-
FASEB J
Role of the CCL20/CCR6 axis in tubular epithelial cell injury: Kidney-specific translational insights from acute kidney injury to chronic kidney disease. [Abstract]2024 Jan 31;38(2):e23407. PMID: 38197598
Solvente y solubilidad
In Vitro:
DMSO : ≥ 100 mg/mL (313.20 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1320 mL | 15.6602 mL | 31.3205 mL | 78.3012 mL |
| 5 mM | 0.6264 mL | 3.1320 mL | 6.2641 mL | 15.6602 mL | |
| 10 mM | 0.3132 mL | 1.5660 mL | 3.1320 mL | 7.8301 mL | |
| 15 mM | 0.2088 mL | 1.0440 mL | 2.0880 mL | 5.2201 mL | |
| 20 mM | 0.1566 mL | 0.7830 mL | 1.5660 mL | 3.9151 mL | |
| 25 mM | 0.1253 mL | 0.6264 mL | 1.2528 mL | 3.1320 mL | |
| 30 mM | 0.1044 mL | 0.5220 mL | 1.0440 mL | 2.6100 mL | |
| 40 mM | 0.0783 mL | 0.3915 mL | 0.7830 mL | 1.9575 mL | |
| 50 mM | 0.0626 mL | 0.3132 mL | 0.6264 mL | 1.5660 mL | |
| 60 mM | 0.0522 mL | 0.2610 mL | 0.5220 mL | 1.3050 mL | |
| 80 mM | 0.0392 mL | 0.1958 mL | 0.3915 mL | 0.9788 mL | |
| 100 mM | 0.0313 mL | 0.1566 mL | 0.3132 mL | 0.7830 mL |
CCR6 antagonist 1 Related Classifications
HY-151435 Related Classifications
Powered by Bioz